The Personalised Medicine Centre aims to develop treatments and clinical tools that take into account a person’s individual genetic and molecular signatures. By understanding the interplay of disease with the sequence, expression level, and activation states of genes and other molecules within our bodies, we are creating a new generation of treatments and robust diagnostics to inform clinical decision making across a range of chronic and degenerative diseases.
Since its inception in 2013, the centre has secured more than £24m in competitive grant funding and published more than 380 peer-reviewed articles in prestigious top quartile journals (correct as of May 2022). At the forefront of innovation in personalised and precision medicine, the centre has secured 14 patent applications in novel therapeutic and diagnostic advances.
The centre contributed to Ulster University’s ranking in the top five universities in the UK in research power in the Allied Health Professions, with 95% of our impact in REF2021 judged to be world-leading or internationally excellent. Across a wide range of world-class research, the centre has developed a global network of partners and collaborative relationships with leading academic institutions and biotechnology, pharmaceutical, data analytics and healthcare sectors.
The centre was established in October 2013 by Professor Tony Bjourson with the award of an £11.5 million grant (European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for N. Ireland, InvestNI, the Northern Ireland Public Health Agency (HSC R&D), ILEX & Ulster University).
Our expertise in data analytics, translational medicine, and biomarker discovery, spans the following disease areas:
- Alzheimer’s disease
- Blood cancers
- Cardiovascular health
- Mental health
- Neuromuscular health
- Rheumatoid Arthritis
See our Research section for more information.